Dr Anup Rawool, Consultant in Clinical and Cancer Genetics at Sahyadri Hospitals, Pune, discusses innovative therapies and ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

Protalix saw record revenue growth in 2024, driven by increased sales to Chiesi, Pfizer, and Brazil. The company aims to start a Phase 2 trial for PRX-115 in 2025.

PLX READ THE FULL PLX RESEARCH REPORT 2024 Financial and Operational Review Protalix Biotherapeutics, Inc. (NYSE:PLX) announced 2024 financial and operational results in a March 17th, 2024 press ...

Feb. 4, 2025 — Research has shown that a potential new targeted therapy for childhood brain cancer is effective in infiltrating and killing tumor cells in ... How Healthy Stem Cells Turn Into Or ...

Protalix BioTherapeutics, Inc. , a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® ...

Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel, March 17, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: ...

Cell growth usually refers to cell proliferation, the increase in cell numbers that occurs through repeated cell division. Cell growth can also refer to the enlargement of cell volume, which can ...

The trailblazers – Genzyme’s Henri Termeer chief among them with development of the first therapy to treat Gaucher disease – quickly recognised the vital role of external stakeholders to get ...

a groundbreaking study has now focused on their jigsaw puzzle-like pattern. This arrangement helps cells tolerate changes in fluid pressure, such as swelling.